Factor Xa inhibitors in acute coronary syndromes: moving from mythology to reality

This publication has 15 references indexed in Scilit:

• Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary RevascularizationREPLACE-2 Randomized Trial
  JAMA, 2004
• Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non–ST-Segment Elevation Acute Coronary Syndromes
  JAMA, 2004
• A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes: The Pentasaccharide in Unstable Angina (PENTUA) study
  Journal of the American College of Cardiology, 2004
• Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor
  Journal of Medicinal Chemistry, 2003
• Secondary Prophylaxis with Warfarin for Venous Thromboembolism
  New England Journal of Medicine, 2003
• Antithrombotic drug market
  Nature Reviews Drug Discovery, 2003
• Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison
  The Lancet, 2002
• Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial
  The Lancet, 2002
• Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery
  New England Journal of Medicine, 2001
• Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee Surgery
  New England Journal of Medicine, 2001